M ultiple sclerosis (MS) is a chronic disorder characterized pathologically by CNS inflammation, demyelination, and neurodegeneration. MS is believed to be caused by the disruption of immunological self-tolerance to CNS myelin in genetically susceptible individuals (1) . Due to their ability to function as professional APCs, dendritic cells (DCs) are thought to play a pivotal role in deciding tolerance versus autoimmunity in MS. In experimental autoimmune encephalomyelitis (EAE) in mice, a model that closely mimics pathological features observed in MS, DCs are essential APCs for the induction of encephalitogenic T cell responses and are also a prominent component of CNS-infiltrating cells (2) . However, other data indicate that DCs may also act in the induction of regulatory T (Treg) cells and that tolerogenic DCs provide the capacity to suppress ongoing EAE (3) . These properties make the modulation of DCs for the induction of tolerance an attractive therapeutic strategy in MS and render the characterization of endogenous factors that contribute to the functional development of tolerogenic DCs highly relevant (4) .
Hepatocyte growth factor (HGF) (5) is a pleiotropic cytokine and a natural ligand for c-Met, a tyrosine kinase receptor that transduces its multiple biological actions in a wide variety of cell types. Within the hematopoietic compartment, c-Met is found constitutively expressed on progenitor cells and their Agpresenting progeny, including DCs, but is absent from T cells (6) . Originally identified as a mitogen for hepatocytes, HGF acts as a potent regulator in multiple animal models of immunemediated disorders (7) (8) (9) (10) , which suggests that HGF regulates key inflammatory events that are common to many diseases and organ systems. In particular, HGF has been demonstrated to re-strain the Ag-presenting function of mouse DCs (7) and to govern the development of Treg cell-inducing regulatory DCs (11, 12) . We recently suggested that such a mechanism might account for the protective role of CNS-restricted overexpression of HGF in myelin oligodendrocyte glycoprotein (MOG)-induced EAE (11) . From an immunologic and therapeutic standpoint, it is important to understand the molecular basis involved in DC immunoregulation by HGF.
In addition to protective autoimmunity, HGF plays functional roles in the CNS. HGF acts as a neurotrophic factor for a variety of neurons and exerts neuroprotective and regenerative effects in various animal models (13) (14) (15) . All of these properties may underlie the recently reported clinical benefit of human mesenchymal stem cell therapy through the HGF-c-Met pathway in immune-and nonimmune-mediated demyelination models (16) . Consistent with these properties, recent advances in humans indicate that HGF levels increase in MS patients during immunomodulatory drug therapy (17) and may play an additional beneficial role in MS by stimulating mechanisms that govern the repair of damaged tissue (18) .
In the current study, we identify a central role for DCs in mediating the immunomodulatory effects of HGF in MOG-induced EAE, an acute T cell-mediated attack of the CNS that results in chronic functional deficits. Using biodegradable microspheres for the controlled release of HGF, systemic treatment with HGF reduced disease severity and induced tolerance in the DC population. HGF-treated DCs were characterized by increased programmed death ligand 1 (PD-L1) expression and ability to promote the development of IL-10-secreting Treg cells. In DCs, HGF induced glucocorticoid-induced leucine zipper (GILZ), the most prominent mediator of glucocorticoid-induced immunosuppression (19) . RNA interference-directed inhibition of GILZ expression by DCs suppressed the induction of tolerance caused by HGF. In adoptive transfer studies, HGF treatment of wild-type (WT) DCs, but not GILZ gene-deficient DCs, potently mediated functional recovery in mice with established EAE. Because DCs play an important role in inciting CNS autoimmunity, the identification of GILZ signaling in mediating the immunoregulatory effect of HGF on DCs furthers our mechanistic understanding of the protective role of HGF in autoimmune neuroinflammation. ) female mice were purchased from Janvier Laboratories (France). 2D2 mice in a C57BL/6J background expressing a TCR specific for the MOG 35-55 (MOG) peptide were kindly provided by V.K. Kuchroo (Harvard University, Boston, MA). C57BL/6J GILZ knockout (KO) (20) and littermate control mice were provided by C. Riccardi (University of Perugia, Perugia, Italy). Mice were kept in accordance with the guidelines of the Geneva University School of Medicine (protocol number 1005/ 3741/3).
Materials and Methods

Induction and evaluation of EAE
Mice were immunized s.c. in the flanks with 100 mg MOG peptide (MEVGWYRSPFSRVVHLYRNGK; Anawa Trading) in complete CFA (DIFCO Laboratories), and 300 ng pertussis toxin (Sigma-Aldrich) in PBS was administered i.v. on days 0 and 2. Individual animals were observed daily, and clinical scores were assessed with a 0-5-point scoring system as follows: 0, no clinical disease; 1, loss of tail tone only; 2, mild monoparesis or paraparesis; 3, severe paraparesis; 4, paraplegia and/or quadriparesis; and 5, moribund or death. Moribund mice were given disease severity scores of 5 and euthanized. For adoptive transfer experiments, splenocytes (5 3 10 6 cells/ml) from 2D2 (TCR-specific MOG) transgenic mice, prepared as a single-cell suspension, were cultured alone or with HGF (30 ng/ml) and stimulated with 20 mg/ml MOG in the presence of (5 mg/ml) IL-2 (R&D Systems) for 2 d, followed by expansion with IL-2 (5 mg/ml) for 4 additional d. Restimulation was performed on day 7 with 0.5 mg/ml plate-bound anti-CD3 and 1 mg/ml anti-CD28 for 24 h in the presence of 20 ng/ml IL-12 and IL-18 (R&D Systems). Activated CD4 + T cells that remained alive after culture were adoptively transferred into WT recipient mice via i.p. injections (7 3 10 6 cells/mouse). Animals received 300 ng/mouse pertussis toxin on days 0 and 2 after T cell transfer.
Reagents
Human recombinant HGF (hrHGF) with a 5-aa deletion in the first kringle domain (Kringle Pharma, Osaka, Japan) was supplied by H. Funakoshi (Asahikawa Medical University) and T. Nakamura (Osaka University, Osaka, Japan) (5). Human HGF (hHGF) can function not only in human, but also in murine tissues. Acidic gelatin hydrogel microspheres with an average diameter of 30 mm were provided by Y. Tabata (Kyoto University, Kyoto, Japan) (21) . Freeze-dried gelatin microspheres (2 mg) were incubated with PBS (control) or PBS containing hrHGF (5 mg/ml) for 24 h at 4˚C for complete absorption. Animals received a single s.c. injection (100 ml) of gelatin hydrogel microspheres with hrHGF (100 mg) or vehicle.
Purification of mouse splenic CD4
+ T cells and CD11c + DCs
Mouse splenic CD4 + T cells were negatively selected using an anti-mouse CD4 + T cell isolation kit (Miltenyi Biotec). To obtain DCs, spleens were minced and incubated with DNase I (1 mg/ml) and Liberase HI (Roche) (0.5 mg/ml) for 15 min at room temperature. Cold EDTA was added to a final concentration of 20 mM, and cell suspensions were incubated for 5 min at room temperature before filtering through nylon mesh to remove tissue and cell aggregates. Highly pure splenic DCs were subsequently positively selected using anti-mouse CD11c colloidal superparamagnetic microbeads (Miltenyi Biotec), as reported previously (11) . The purity of CD4 + and CD11c + cells, confirmed by flow cytometry, was routinely .95 and .85%, respectively.
In vitro T cell and DC coculture assays
Splenic DCs (1 3 10 5 cells/ml) were pulsed with MOG (20 mg/ml) for 24 h and then cocultured in medium with TCR MOG CD4 + (2D2) T cells (1 3 10 6 cells/ml) for 72 h. In certain experiments, splenic CD11c + cells were isolated from nonpathological WT or GILZ KO mice or, at the time of sacrifice, from EAE mice that received gelatin hydrogel microspheres incorporating hrHGF (100 mg) or vehicle. 
T cell proliferation assay
Adoptive transfer of DCs
CD11c + cells of up to 95% purity were isolated from spleens of 8-10-wk-old C57BL/6J GILZ KO or WT littermate mice by positive MACS (Miltenyi Biotec). Purified CD11c + cells (1 3 10 6 cells/ml) were cultured alone or with HGF (30 ng/ml) for 24 h, followed by a 4-h pulsing period with MOG (20 mg/ml), and immediately transferred into recipient mice. Recipient C57BL/ 6J mice were immunized with MOG, randomized at EAE score 1 or 2, and injected i.v. with 1 3 10 6 HGF-or vehicle-treated MOG-pulsed DCs.
RNA-mediated interference
GILZ gene expression silencing in DCs was obtained with a mixture of 20 nmol small interfering RNA (siRNA) specific for GILZ mRNA (siGILZ; Microsynth) and X-tremeGENE siRNA transfection reagent (Roche Diagnostics) according to the manufacturer's instructions.
ELISA
IL-12p70, IL-12p40, IL-27, IL-10, IL-6, IL-17A, IFN-g, GM-CSF, murine HGF (mHGF), and hHGF were detected in culture supernatants using ELISA sets from eBioscience or R&D Systems according to the manufacturer's instructions. Serum was isolated after coagulation and centrifugation (5 min at 3000 3 g) and kept frozen at 220˚C until use. For measurement of tissue HGF concentration, spleen from mice was ho-mogenized in an extraction buffer containing 20 mmol/l Tris-HCl (pH 7.5), 2 mol/l NaCl, 0.1% Tween-80, 1 mmol/l EDTA, and 1 mmol/l PMSF. After centrifugation (19,000 3 g for 20 min at 4˚C), the supernatant was recovered for determination of mHGF and hHGF. Total protein levels were determined using a Bradford assay (Sigma-Aldrich) with BSA as a standard. The concentration of HGF in organs was expressed as nanograms per milligram total protein.
Isolation of CNS-infiltrating mononuclear cells
At the time of sacrifice, mice were perfused through the left cardiac ventricle with cold PBS. Spinal cords were extruded by flushing the vertebral canal with cold PBS and minced with a scalpel blade. The spinal cords were forced through 100-mesh stainless steel screens (Falcon; BD Biosciences) to obtain a single-cell suspension in HBSS containing 300 U/ml per cord type IV clostridial collagenase (Sigma-Aldrich) and then incubated for 1 h at 37˚C. Infiltrates were isolated on Percoll (GE Healthcare).
Histopathology and immunostaining
Spinal cords obtained from transcardially perfused mice (4% paraformaldehyde) at the sacrifice time (day 21 postimmunization) were embedded in paraffin (n = 3 animals/experimental group). Paraffin-embedded blocks were cut into sections (3 mm thickness) and stained with H&E to assess inflammation or Luxol Fast Blue/periodic acid-Schiff stain to assess the degree of demyelination. Quantification was performed by examining 11 transverse sections from the cervical to lumbar spinal cord. The number of lesions per spinal cord section was averaged to calculate the inflammatory index. Extent of demyelination was expressed as percent of total white matter analyzed (set as 100%).
Immunologic markers and flow cytometry
Single-cell suspensions from spleens and spinal cords were incubated in blocking solution (PBS with 1% FCS) for 20 min on ice prior to staining to block nonspecific Fc-mediated interactions and then stained for 30 min at 4˚C with FITC, PE, PerCP-Cy5, or allophycocyanin fluorochromes conjugated with Abs (1:100) against: CD11c, MHC class II, CD40, CD86, c-Met, PD-L1, GILZ, CD4, CD44, CD62L, and CD25 (all Abs from eBioscience) or appropriate fluorochrome-conjugated, isotype-matched irrelevant Abs to establish background fluorescence. For intracellular cytokine staining of IFN-g, IL-17, and IL-10 (eBioscience), T cells were stimulated with PMA (50 ng/ml) plus ionomycin (500 ng/ml) in the presence of brefeldin A (10 mg/ml; Sigma-Aldrich) and then fixed and permeabilized using BD Cytofix/Cytoperm Plus Kit (BD Biosciences). Foxp3 staining was performed according to the manufacturer's protocol (FJK-16s; Mouse Treg Cell Staining Kit; eBioscience). Samples were processed on an FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo analysis software (version 9.3.2; Tree Star).
Western blotting
Purified splenic DCs cultured in vitro in different conditions were homogenized using a polytron in lysis buffer (50 mM Tris-HCl [pH 7.5], 250 mM NaCl, 1% Triton X-100, 1 mM EDTA, and 1 mM DTT) containing complete protease inhibitors (Roche). Equal amounts (20 mg) of total protein from each sample were transferred to a 15% SDS-polyacrylamide gel and blotted onto an Immobilon-P PVDF membrane (Millipore). GILZ protein was detected using properly diluted (1/100) rat anti-mouse anti-GILZ Ab (eBioscience), followed by a peroxidase-conjugated secondary Ab to rat IgG (Jackson ImmunoResearch laboratories) and then visualized using chemiluminescence (Supersignal; Pierce). The blot was also probed with b-actin mAb as a loading control (Sigma-Aldrich).
RNA isolation and real-time quantitative PCR
RNA was prepared from MACS-sorted DCs using Qiagen RNAeasy Mini Kits (Qiagen) and subjected to DNase I (Roche Diagnostics) digestion. Random hexamer primers (Promega, Madison, WI) and Superscript II RNase H reverse transcriptase (Invitrogen, Carlsbad, CA) were used to generate cDNA. GILZ transcripts were quantified by real-time PCR analysis using SYBR Green as the detection agent. The PCR was performed with the Bio-Rad iCycler iQ system (Bio-Rad). GILZ mRNA expression was normalized to b-actin expression and quantified using the relative standard curve method, followed by comparison with the results from control samples (unmanipulated DCs). For all reactions, each condition was performed in triplicate. Each experiment was repeated at least three times.
RNA-mediated interference
Freshly purified splenic DCs were incubated with a mixture of 20 nmol siGILZ (Microsynth) and X-tremeGENE siRNA transfection reagent (Roche 
Serum corticosterone levels
Measurement of corticosterone in serum was performed by an enzyme immunoassay kit (Enzo Life Sciences, Lausen, Basel, Switzerland) according to the manufacturer's instructions. The detection limit was 27 pg/ml. Serum was isolated after coagulation and centrifugation (5 min at 3000 3 g) and kept frozen at 220˚C until use.
Detection of anti-hrHGF Abs
Serum hrHGF-specific IgG was quantified using a noncommercial ELISA. The 96-Maxisorb plates (Costar) were coated with hrHGF protein (10 mg/ml in PBS), blocked with BSA (Sigma-Aldrich), and incubated with sera overnight at 1:250 dilution. After washing, hrHGF-specific IgG retained by the plate-bound hrHGF was detected with HRP-conjugated anti-mouse IgG (Immuno-Tek). The positive control was performed with a mouse monoclonal anti-human full-length HGF Ab (R&D Systems) using 2-fold serial dilution (0.0315-0.5 mg/ml). BSA-coated plates were used as negative controls for nonspecific binding. SOFTmax ELISA plate reader (405-nm wavelength) and software (Molecular Devices) were used for data analysis.
Statistical analysis
All of the statistical analyses were performed by GraphPad Prism for Mac, version 5.0 (GraphPad).
Results
Controlled release of HGF attenuates development of MOG-induced EAE
Generally, i.v. injections of HGF exert only short-term effects on target organs and do not produce continuous effects (16) . To achieve effective delivery of HGF, we selected biodegradable gelatin hydrogels as a carrier for hrHGF and administered the hrHGF/gelatin complex by s.c. injection (21) . Without altering the concentration of endogenous mHGF, sustained and supraphysiologically relevant (3-fold) hrHGF levels in sera and spleens were detected in EAE mice for at least 10 d after s.c. injection of the gelatin/hrHGF complex (henceforth referred to as HGF) (Fig. 1A, 1B) . HGF treatment significantly suppressed the severity of MOG-induced EAE without a reduction in disease incidence (Fig. 1C , Table I ). Histological examination at the sacrifice time (day 21) demonstrated that HGF-treated mice had reduced CNS inflammatory infiltration and demyelination as compared with mice treated with vehicle (Fig. 1D ). In addition, mice treated with HGF showed higher IL-10 ( Fig. 1E , left panel) and lower IFN-g (Fig. 1E , right panel) production from CNS-infiltrating CD4 + T lymphocytes compared with control mice at the latest time point. (Fig. 2B, top panel) , and IL-10-producing Treg cells (Fig. 2B, bottom panel) . Correspondingly, mice that received HGF treatment showed a reduced proportion of activated CD44 high CD62L low CD4 + T cells (Fig. 2A, bottom  panel) and a 2-fold reduction in the frequencies of both IFN-g + and IL-17 + splenic CD4 + T cells (Fig. 2C) . These results indicate (Fig. 2D) .
HGF enhances Treg cells and limits encephalitogenic T cell responses in EAE
HGF redirects T cell immune responses by modulating APC functions
Next, we explored the ability of HGF to mediate immune modulation by altering APC function. Highly pure DCs were isolated from EAE mice treated or not with HGF (30 ng/ml) and tested as APCs for the stimulation of naive MOG-specific TCR transgenic (2D2) T cells in the presence of MOG. Significant reductions in the level of 2D2 T cell proliferation (Fig. 3A) and the production of Gelatin/PBS 10/10 11.5 6 1.1 239 6 6.9 221.4 6 6.4 Gelatin/hrHGF 10/10 13.1 6 1.1* 142 6 7.3** 131.1 6 6.8** C57BL/6J mice received a single injection of gelatin/PBS (n = 10) or gelatin/hrHGF complex (n = 10) 2 d before immunization (MOG). The mean day of onset was calculated by averaging the first day of clinical signs of individual mice within each group. The total score was calculated by summing all the scores obtained on the clinical scale over the time frame being analyzed. The area under the curve (AUC) was calculated from the EAE clinical course for each mouse between days 0 and 21 postimmunization. Differences in the mean day of onset, total score, and AUC, were analyzed by Mann-Whitney U test (experiment versus treatment group) for the data in Fig. 1C . Each mean value was reported with the SD. Results are representative of two separate experiments (10 mice/group/experiment).
*p , 0.05, **p , 0.01.
IFN-g, IL-17, and GM-CSF (Fig. 3B) were observed when HGFtreated DCs were used as APCs. There was a corresponding decrease in the frequency of 2D2 T cells with an activated CD44 high CD62L low phenotype (Fig. 3C, bottom panel) and a paralleled increased number of CD4 + T cells that retained the naive phenotype (CD44 low CD62L high ) (Fig. 3C , top panel) when cultured with DCs from HGF-treated mice. Moreover, after coculture with DCs from HGF-treated mice, significant increases were observed in the proportions of Treg cells (Fig. 3D ) (4.1 6 0.4, mean 6 SEM; n = 3) and IL-10-producing 2D2 CD4 + T cells (Fig. 3E ) (3.6 6 0.9, mean 6 SEM; n = 3). Similar results were obtained when the different cell populations were calculated as absolute numbers (Fig. 3F) .
HGF induces regulatory DCs characterized by increased expression of PD-L1 and GILZ
Because APCs directed T cell immune modulation in HGF treatment, we evaluated the cytokines produced by DCs of mice immunized with MOG. As described in Fig. 4A , DCs from HGFtreated EAE mice exhibited a tolerogenic phenotype, characterized by reduced cellular production of the proinflammatory-polarizing Th1 cytokines IL-12 (p70) and IFN-g as well as decreased production of the IL-12/IL-23 p40 subunit. HGF treatment further showed increased production of the Th17 cell-inhibiting cytokine IL-27 by DCs with no effect on IL-6 production. In these conditions, IL-10 production by DCs was very low in each group of mice and did not allow appropriate comparison. Flow cytometric analysis, however, revealed that HGF treatment was consistently associated with significantly increased IL-10 and PD-L1 expression in DCs, whereas HGF did not affect the expression of MHC class II or CD86 (Fig. 4B) . As previously demonstrated (11), DCs from HGF-treated EAE mice exhibited reduced CD40 expression (Fig. 4B) . During the search for molecules enabling tolerization of DCs, we addressed the expression of GILZ, an important gene reported to promote the differentiation of DCs into Treg cell-inducing regulatory DCs. Flow cytometry analyses of splenic DCs from EAE animals treated or not with HGF revealed that in vivo HGF treatment increased GILZ protein expression in DCs (Fig. 4B) , providing a potential molecular mechanism underlying the tolerogenic function of HGF in DCs.
GILZ expression directs the induction of tolerogenic DCs by HGF in vitro
Using adoptive transfer EAE experiments, we further established that in vitro treatment of DCs with HGF could limit the full development of encephalitogenic potential in autoreactive T cells, hence recapitulating the in vivo biologic action of HGF delivery in EAE (Fig. 5A) . Mechanistically, HGF-treated DCs in vitro reduced MOG-reactive T cell proliferation (Fig. 5B) and induced greater frequencies of myelin Ag-specific IL-10-producing Treg cells (Fig. 5C) . As a crucial mediator of the anti-inflammatory and immunosuppressive activity of glucocorticoids (GCs), we chose to The Journal of Immunologyfurther investigate the functional significance of GILZ with respect to the immune-regulatory properties of HGF. Similar to the control treatment with dexamethasone, a potent GILZ inducer in DCs (22) , HGF treatment induced high expression of GILZ mRNA (Fig. 6A) and protein (Fig. 6B) in DCs. Using in vitro cocultures in which DCs were used as APCs with naive CD4 + MOG-specific TCR (2D2) T cells and MOG Ag, selective neutralization of GILZ expression in DCs by RNA interference-based silencing (Fig. 6C, 6D ) further established an essential role for GILZ expression in restraining T cell activation (Fig. 6E, top  panel) and in stimulating Treg cell differentiation (Fig. 6E , bottom panel) and T cell IL-10 production (Fig. 6F) by HGF-treated DCs.
Expression of GILZ by DCs is essential for HGF treatment to have protective effects in EAE
To confirm the involvement of tolerogenic DCs in EAE suppression by HGF and the importance of GILZ signaling in this mechanism, we performed adoptive transfer of DCs into recipient mice with established EAE (score 1). Highly pure splenic DCs isolated from nonpathological WT and GILZ-deficient mice were subjected to HGF treatment prior to adoptive transfer; control cells were not subjected to HGF treatment. Compared with the transfer of vehicle-treated control cells, adoptively transferred HGF-tolerized DCs from WT mice markedly blocked EAE progression and reduced clinical severity (Fig. 7A) . Importantly, the adoptive transfer of HGF-treated DCs from GILZ KO mice did not alter EAE severity (Fig. 7A) , which suggests that expression of GILZ in DCs is essential for the protection mediated by HGF against EAE. HGF-treated WT DCs also potently reduced EAE in mice with greater disease severity (Supplemental Fig. 1) . Mechanistically, improvement of clinical EAE correlated with the capacity of HGF-treated DCs to significantly increase the percentage of Treg cells and IL-10-producing CD4 + T cells and to reduce that of both Th1 and Th17 effector cells (Fig. 7B) .
Complementary in vitro studies revealed that HGF-treated DCs from WT, but not GILZ KO mice, reduced the T cell proliferation (Fig. 7C) and differentiation of cytokine production associated with Th1 and Th17 cells (Fig. 7D ). An expansion in the frequency of Treg cells was observed when we examined cultures using HGF-treated DCs from WT, but not GILZ KO, mice as APCs (Fig. 7E) . DCs from WT and GILZ KO mice demonstrated similar surface expression of the HGF receptor c-Met ( Fig. 7F) , ruling out the possibility that the defective tolerogenic effect of HGF on GILZ KO DCs was due to altered c-Met expression. Altogether, these data confirmed that by acting via GILZ, HGF is an important signal to prompt DCs to suppress T cell responses and promote tolerance.
Discussion
DCs are considered as the most potent APCs, capable of promoting Ag-specific immune responses in either an immunogenic or tolerogenic manner. Consequently, the identification of biological or pharmacological agents that promote tolerogenicity of DCs has The Journal of Immunologyreceived considerable attention regarding their application in the treatment of chronic immune-mediated conditions. Although the exact mechanism remains elusive, recent advances suggest that HGF can generate tolerogenic DCs capable of promoting the development of Treg cells with suppressive activity. In this study, we examined the potential therapeutic properties of peripheral administration of HGF in the development and progression of MOG peptide-induced EAE, a prototypical animal model of T cell-driven autoimmune disease and, more specifically, of MS pathogenesis. We found that systemic HGF prevented autoimmunemediated inflammation and demyelination and was associated with the development of DCs with a typical tolerogenic phenotype in vivo. We observed a significant increase in the frequency of both peripheral and CNS anti-inflammatory Treg cells and a concomitant decrease of proinflammatory Th1 and Th17 responses. This effect was independent of the action of HGF on the hypothalamic-pituitary-adrenal axis (Supplemental Fig. 2A) , a crucial immunoregulatory pathway, or inhibition of DC activation via the formation of immune complexes (Supplemental Fig. 2B ). Consistent with a role for immune tolerance induced by HGF, we demonstrated that HGFtreated DCs suppressed the encephalitogenic potential of myelinreactive T cells to adoptively transfer EAE. The observation that HGF-treated DCs were able to reverse established EAE in recipient mice after adoptive transfer and that clinical improvement was associated with reduced proinflammatory Th1 and Th17 responses and elevation of Treg cells further supports this premise.
EAE amelioration by HGF treatment was associated with impaired CD40 expression on DCs, a finding consistent with an important role of DC-expressed CD40 to evoke T cell-activation and CNS autoimmunity (23) . Moreover, in agreement with data reporting PD-L1 as necessary for the DC-mediated induction of Treg cells (24) and tolerance, our results indicate that HGF treatment significantly increases PD-L1 expression by DCs. Although these immunomodulating mechanisms may confer the regulatory properties of HGF-treated DCs, it does not provide the molecular mechanisms by which HGF generates tolerogenic DCs. Generally, immunomodulatory cytokines such as IL-10, or TGF-b1, or immunosuppressive agents such as GCs, used alone or in combination, promote the development of regulatory DCs (4). A common trait of tolerogenic DCs generated by IL-10, GCs, and TGF-b1 is the expression of GILZ (25) . Expression of the GILZ molecule by DCs allows the induction of Treg cells and prevents DCs from activating Ag-specific T cells (22, 25) . In this study, we show that HGF has a strong stimulatory effect on GILZ expression in DCs. Downregulation of GILZ by RNA interference fully restored Ag presentation by HGF-treated APCs, and GILZ deficiency abrogated the tolerogenic properties of adoptively transferred HGF-treated DCs on EAE. These findings further validate a major role for GILZ expression in determining whether DCs stimulate T cells.
HGF has been reported to ameliorate the progression of a number of inflammatory autoimmune diseases, including allergic airway inflammation (7), myocarditis (8) , lupus nephritis (9), and arthritis (10) , suggesting that HGF may interfere with a common proinflammatory process. The protective actions of HGF in all of these various organ system dysfunctions were tightly associated with the modulation of T cell immune responses, supporting a potent regulation of DC function. Mechanistically, HGF was reported to inhibit DC activation in vitro by disrupting NF-kB signaling via Bruton's tyrosine kinase and a downstream signaling cascade involving sequential activation of the PI3K/AKT pathway and mammalian target of rapamycin (26) . In this study, our in vitro and in vivo studies further delineate the molecular events by which HGF confers regulatory functions to DCs. Consistent with our findings, GILZ has been reported to modulate myeloid APC activities by inhibiting key inflammatory transcription factors, including NF-kB and AP-1 (27) , and to drive DCs to an alternative differentiation pathway leading to cells with many features of tolerogenic DCs (25) .
Experimental studies in EAE suggest that reactivation of encephalitogenic T cells by local CNS APCs presenting self-Ags is crucial for the initiation of autoimmune neuroinflammation (28) and that DC functions are essential for both the peripheral stimulation and central reactivation of myelin-specific T cells (2) . In the EAE process, we have recently reported that selective HGF overexpression by neurons suppressed disease and was associated with increased frequencies of classical Treg cells and reduced production of IFN-g and IL-12p70 within the spinal cord (11) . Although no modulation in peripheral T cell activation was observed in this transgenic model, we demonstrate in this study that HGF reduces EAE by modulating peripheral T cell immune responses that are important for the development of the disease through the alteration of DC functions. Altogether, our studies thus indicate that HGF has the ability to ameliorate CNS autoimmunity by controlling the development of regulatory DCs in both the peripheral compartment and CNS tissues. Complementary to our findings, therapeutic administration of exogenously supplied HGF was recently reported to reduce functional deficits in mouse MOG-induced EAE and to promote the development of oligodendrocytes and neurons (16) . Although the molecular and cellular mechanisms by which HGF affects immune responses were not addressed, our current findings suggest that induction of GILZ synthesis may potentially support HGF-mediated immunosuppression by regulating DC functions. Hence, in addition to the direct reported roles of HGF in neuroprotection and neurorepair (16) , the development of regulatory cells by HGF may confer indirect neuroprotection owing to the prevention of inflammatory damage.
The cumulative results of this study support the notion that Th1 and Th17 suppression with parallel elevation in Treg cells are central mechanisms underlying the immunomodulatory effect of HGF in experimental autoimmune neuroinflammation. We estab- 
